Takefumi Ishidao

Title: Takefumi Ishidao: Innovator in Tumor Research

Introduction

Takefumi Ishidao is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of tumor research, particularly through his innovative work on enhancing the expression of specific genes related to tumor formation.

Latest Patents

Takefumi Ishidao holds a patent for an sFRP expression enhancing agent. This invention addresses tumor formation and the reduced transcription of both the sFRP1 and sFRP2 genes in Dlg gene knock-out mice. The patent provides a comprehensive approach that includes an agent for enhancing the expression and/or function of sFRP, which contains a compound that enhances Dlg's expression and function. Additionally, it outlines methods for inhibiting tumor formation and preventing or treating tumor diseases, utilizing the enhancing agent or method. The patent also describes a non-human mammal deficient in one or both Dlg alleles, a cell originating from this mammal, and methods for identifying compounds and examining tumor tissues or cells.

Career Highlights

Throughout his career, Takefumi Ishidao has worked with notable organizations, including Daiichi Pharmaceutical Co., Ltd. and Kyushu University. His work has been instrumental in advancing the understanding of tumor biology and potential therapeutic strategies.

Collaborations

Takefumi has collaborated with esteemed colleagues such as Tetsu Akiyama and Tomoiki Aiba. Their joint efforts have contributed to the development of innovative solutions in the field of cancer research.

Conclusion

Takefumi Ishidao's contributions to tumor research through his patent and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in cancer treatment and understanding.